Clifford V Harding Selected Research

Histocompatibility Antigens Class II

6/2015	Toll-like receptor 2-dependent extracellular signal-regulated kinase signaling in Mycobacterium tuberculosis-infected macrophages drives anti-inflammatory responses and inhibits Th1 polarization of responding T cells.
12/2010	Mycobacterium tuberculosis synergizes with ATP to induce release of microvesicles and exosomes containing major histocompatibility complex class II molecules capable of antigen presentation.
9/2010	Mycobacterium tuberculosis promotes HIV trans-infection and suppresses major histocompatibility complex class II antigen processing by dendritic cells.
4/2010	Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors.
10/2009	Mycobacterium tuberculosis cell wall glycolipids directly inhibit CD4+ T-cell activation by interfering with proximal T-cell-receptor signaling.
3/2006	Role of phagosomes and major histocompatibility complex class II (MHC-II) compartment in MHC-II antigen processing of Mycobacterium tuberculosis in human macrophages.
2/2005	Phagosomal processing of Mycobacterium tuberculosis antigen 85B is modulated independently of mycobacterial viability and phagosome maturation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Clifford V Harding Research Topics

Disease

21	Tuberculosis (Tuberculoses) 10/2018 - 08/2002
17	Infections 04/2016 - 08/2003
3	Disease Progression 01/2021 - 05/2009
3	Neoplasms (Cancer) 11/2018 - 06/2005
3	HIV Infections (HIV Infection) 10/2014 - 06/2006
2	COVID-19 01/2021 - 08/2020
2	Dementia (Dementias) 01/2021 - 11/2014
2	Inflammation (Inflammations) 12/2020 - 05/2014
2	Acquired Immunodeficiency Syndrome (AIDS) 11/2018 - 01/2012
2	Parkinson Disease (Parkinson's Disease) 02/2016 - 11/2014
2	Persistent Infection 06/2006 - 08/2003
2	Rheumatoid Arthritis 02/2006 - 01/2006
1	Alzheimer Disease (Alzheimer's Disease) 01/2021
1	Sarcoidosis (Schaumann Disease) 01/2021
1	Ventricular Tachycardia 01/2021
1	Thrombocytopenia (Thrombopenia) 08/2019
1	Breast Neoplasms (Breast Cancer) 11/2016
1	Neurodegenerative Diseases (Neurodegenerative Disease) 02/2016
1	Lewy Body Disease (Lewy Body Dementia) 02/2016
1	Wound Infection (Wound Infections) 03/2015
1	Synucleinopathies 11/2014
1	Anemia 11/2014
1	Atherosclerosis 05/2014
1	Obesity 05/2014
1	Coinfection 02/2012
1	Latent Infection 04/2010
1	Melanoma (Melanoma, Malignant) 03/2006
1	Arthritis (Polyarthritis) 02/2006

Drug/Important Bio-Agent (IBA)

13	AntigensIBA 04/2016 - 08/2002
8	Peptides (Polypeptides)IBA 01/2016 - 08/2003
7	Lipoproteins (Lipoprotein)IBA 10/2018 - 08/2003
7	Histocompatibility Antigens Class IIIBA 06/2015 - 02/2005
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2003
5	LipopolysaccharidesIBA 10/2018 - 09/2010
4	GlycolipidsIBA 10/2018 - 09/2006
4	lipoarabinomannan (LAM)IBA 10/2018 - 10/2009
4	Interferon Type IIBA 10/2014 - 05/2006
3	Toll-Like Receptor 2IBA 10/2018 - 04/2010
3	phosphatidylinositol mannosideIBA 10/2018 - 09/2006
3	Mannose (D-Mannose)IBA 10/2018 - 10/2009
3	CytokinesIBA 08/2015 - 06/2006
3	LigandsIBA 06/2015 - 02/2008
3	InterferonsIBA 01/2013 - 05/2006
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 05/2006
2	Interleukin-12 (IL 12)IBA 12/2020 - 06/2015
2	RNA (Ribonucleic Acid)IBA 11/2018 - 05/2009
2	lipomannanIBA 10/2018 - 01/2017
2	Interleukin-2 (IL2)IBA 01/2017 - 01/2016
2	Anti-Bacterial Agents (Antibiotics)IBA 03/2015 - 02/2005
2	Messenger RNA (mRNA)IBA 01/2013 - 08/2003
2	Interferon-alpha (Interferon Alfa)IBA 01/2012 - 06/2006
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2010 - 10/2009
2	MHC class II transactivator proteinIBA 04/2010 - 04/2006
2	EpitopesIBA 02/2006 - 02/2005
2	VaccinesIBA 10/2004 - 05/2004
1	HepcidinsIBA 01/2021
1	Angiotensin-Converting Enzyme 2IBA 01/2021
1	Ferritins (Ferritin)IBA 01/2021
1	IronIBA 01/2021
1	Angiotensin Receptor AntagonistsIBA 08/2020
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 08/2020
1	AntibodiesIBA 08/2019
1	Platelet Factor 4IBA 08/2019
1	Heparin (Liquaemin)FDA LinkGeneric 08/2019
1	Toll-Like Receptor 3IBA 11/2018
1	ElementsIBA 11/2018
1	Toll-Like Receptor 1IBA 10/2018
1	Biomarkers (Surrogate Marker)IBA 11/2016
1	alpha-SynucleinIBA 02/2016
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 06/2015
1	Interleukin-10 (Interleukin 10)IBA 06/2015
1	Vancomycin FDA LinkGeneric 03/2015
1	Cephalothin (Cefalotin)FDA Link 03/2015
1	Nafcillin FDA LinkGeneric 03/2015
1	Immunoglobulin G (IgG)IBA 11/2014
1	SynucleinsIBA 11/2014
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 05/2014
1	HIV AntigensIBA 09/2010
1	DNA (Deoxyribonucleic Acid)IBA 08/2010
1	AerosolsIBA 01/2009
1	Chemokine ReceptorsIBA 02/2008
1	Mitogen-Activated Protein KinasesIBA 05/2007
1	p38 Mitogen-Activated Protein KinasesIBA 05/2006
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2006
1	Interferon alpha-beta Receptor (Receptor, Interferon alpha beta)IBA 05/2006
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2006
1	Immune Sera (Antisera)IBA 03/2006
1	CarbohydratesIBA 03/2006
1	MonosaccharidesIBA 03/2006
1	Carbohydrate Tumor-Associated Antigens (Antigens, Tumor-Associated Carbohydrate)IBA 03/2006
1	N-phenylacetylmannosamineIBA 03/2006
1	Conjugate VaccinesIBA 03/2006
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 03/2006
1	Cancer VaccinesIBA 03/2006
1	mannosamine (D-mannosamine)IBA 03/2006
1	PercollIBA 03/2006
1	Collagen Type II (Type II Collagen)IBA 02/2006

Therapy/Procedure

2	Therapeutics 11/2018 - 03/2015
2	Immunotherapy 03/2006 - 01/2006
1	Defibrillators (Defibrillator) 01/2021